中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2013年
12期
916-920
,共5页
朱再生%叶敏%施红旗%周一波%季敬伟%吴汉%孙鹏%陈良佑%刘全启
硃再生%葉敏%施紅旂%週一波%季敬偉%吳漢%孫鵬%陳良祐%劉全啟
주재생%협민%시홍기%주일파%계경위%오한%손붕%진량우%류전계
泌尿肿瘤%癌%淋巴结清扫
泌尿腫瘤%癌%淋巴結清掃
비뇨종류%암%림파결청소
Urologic neoplasms%Carcinoma%Lymphadenectomy
目的 探讨肾盂输尿管癌手术区域淋巴结清扫的临床意义. 方法 回顾性分析1990年1月至2011年1月收治的143例肾盂输尿管癌手术患者资料.男91例,女52例.年龄33~86岁,平均64岁.术中行区域淋巴结清扫67例,未清扫76例.术后TNM分期:清扫组T1、T2、T3、T4期分别为6、9、44、8例,未清扫组分别为21、14、36、5例.病理分级:清扫组G1、G2、G3级分别为3、25、39例,未清扫组为2、38、36例.分析区域淋巴结清扫对生存率和肿瘤复发、转移的影响. 结果 清扫组平均随访56.2个月,未清扫组42.7个月.两组T3~T4期患者的肿瘤复发或进展率分别为19.0%、49.0%(x2=9.16,P<0.01),远处转移率分别为9.6%、31.7%(x2=7.17,P<0.01),组间比较差异有统计学意义.清扫组T1、T2、T3、T4期患者淋巴结转移率分别为0、11.0%、32.0%、78.0%(x2=6.01,P<0.05),G1、G2、G3级淋巴结转移率分别为0、16.0%、46.0%(x2=7.51,P<0.01).两组肿瘤相关性累积生存率分别为77.7%和57.1%(P=0.061),两组T3~T4期患者相关性累积生存率分别为76.2%与29.9% (P=0.017).多因素分析表明,肿瘤分级(P=0.0008)、分期(P=0.0013)及淋巴结清扫(P=0.0087)为预后相关因素. 结论 肾盂输尿管癌手术时行肿瘤区域淋巴结清扫术能更准确地进行肿瘤分期,将显著改善W3 ~ T4期患者的生存.
目的 探討腎盂輸尿管癌手術區域淋巴結清掃的臨床意義. 方法 迴顧性分析1990年1月至2011年1月收治的143例腎盂輸尿管癌手術患者資料.男91例,女52例.年齡33~86歲,平均64歲.術中行區域淋巴結清掃67例,未清掃76例.術後TNM分期:清掃組T1、T2、T3、T4期分彆為6、9、44、8例,未清掃組分彆為21、14、36、5例.病理分級:清掃組G1、G2、G3級分彆為3、25、39例,未清掃組為2、38、36例.分析區域淋巴結清掃對生存率和腫瘤複髮、轉移的影響. 結果 清掃組平均隨訪56.2箇月,未清掃組42.7箇月.兩組T3~T4期患者的腫瘤複髮或進展率分彆為19.0%、49.0%(x2=9.16,P<0.01),遠處轉移率分彆為9.6%、31.7%(x2=7.17,P<0.01),組間比較差異有統計學意義.清掃組T1、T2、T3、T4期患者淋巴結轉移率分彆為0、11.0%、32.0%、78.0%(x2=6.01,P<0.05),G1、G2、G3級淋巴結轉移率分彆為0、16.0%、46.0%(x2=7.51,P<0.01).兩組腫瘤相關性纍積生存率分彆為77.7%和57.1%(P=0.061),兩組T3~T4期患者相關性纍積生存率分彆為76.2%與29.9% (P=0.017).多因素分析錶明,腫瘤分級(P=0.0008)、分期(P=0.0013)及淋巴結清掃(P=0.0087)為預後相關因素. 結論 腎盂輸尿管癌手術時行腫瘤區域淋巴結清掃術能更準確地進行腫瘤分期,將顯著改善W3 ~ T4期患者的生存.
목적 탐토신우수뇨관암수술구역림파결청소적림상의의. 방법 회고성분석1990년1월지2011년1월수치적143례신우수뇨관암수술환자자료.남91례,녀52례.년령33~86세,평균64세.술중행구역림파결청소67례,미청소76례.술후TNM분기:청소조T1、T2、T3、T4기분별위6、9、44、8례,미청소조분별위21、14、36、5례.병리분급:청소조G1、G2、G3급분별위3、25、39례,미청소조위2、38、36례.분석구역림파결청소대생존솔화종류복발、전이적영향. 결과 청소조평균수방56.2개월,미청소조42.7개월.량조T3~T4기환자적종류복발혹진전솔분별위19.0%、49.0%(x2=9.16,P<0.01),원처전이솔분별위9.6%、31.7%(x2=7.17,P<0.01),조간비교차이유통계학의의.청소조T1、T2、T3、T4기환자림파결전이솔분별위0、11.0%、32.0%、78.0%(x2=6.01,P<0.05),G1、G2、G3급림파결전이솔분별위0、16.0%、46.0%(x2=7.51,P<0.01).량조종류상관성루적생존솔분별위77.7%화57.1%(P=0.061),량조T3~T4기환자상관성루적생존솔분별위76.2%여29.9% (P=0.017).다인소분석표명,종류분급(P=0.0008)、분기(P=0.0013)급림파결청소(P=0.0087)위예후상관인소. 결론 신우수뇨관암수술시행종류구역림파결청소술능경준학지진행종류분기,장현저개선W3 ~ T4기환자적생존.
Objective To evaluate the role of regional lymphadenectomy on the survival of patients with upper urinary tract urothelial carcinoma.Methods The data of 143 patients with transitional cell carcinoma of the upper urinary tract (91 males and 52 females; mean age,64 years) with radical nephroureterectomy from January 1990 to January 2011 were analyzed retrospectively.Lymphadenectomy was performed in 67 patients (study group),and was not performed in 76 patients (control group).TNM staging showed stage T1,T2,T3,T4 tumor in 6,9,44,8 cases of study group and 21,14,36,5 cases in control group,respectively.The effect of lymphadenectomy on the survival was retrospectively analyzed.Results Medium follow-up were 56.2 and 42.7 months in 2 groups,respectively.The recurrence rate(19.0% and 49.0%,x2=9.16,P<0.01) and the distant metastatic rate (9.6% and 31.7%,x2=7.17,P<0.01) were significantly different in 2 groups when the T stage was pT3 or higher.The metastatic rates of dissected lymph nodes of stage T1,T2,T3,T4 were 0,11.0%,32.0% and 78.0% (x2=6.01,P<0.05),respectively; the metastatic rates of dissected lymph nodes of grade G1,G2,G3 were 0,16.0%,46.0% (x2 =7.51,P<0.01),respectively.The disease specific survival (77.7% and 57.1%,P=0.061) did not significantly differ between the 2 groups.However,patient survival rates (76.2% and 29.9%,P=0.017) were significantly different in 2 groups when the T stage was pT3 or higher.Multivariate analysis showed that lymphadenectomy (P =0.0087) was a significant grognostic factor for caner specific survival as well as T stage (P =0.0013) and tumor grade (P=0.0008).Conclusions It is suggested that the regional lymph nodes should be resected necessarily.The lymphadenectomy may significantly improve the prognosis of upper urinary tract urothelial carcinoma,especially for patients with advanced disease.